Sample size (n) |
164 |
26 |
116 |
|
Age (mean, SD) |
37.1 (16.7) |
42.8 (16.5) |
37.6 (15.9) |
<0.001 |
Gender |
|
|
|
0.04 |
Male (n,%) |
70 (43%) |
9 (35%) |
33 (28%) |
|
Female (n,%) |
94 (57%) |
17 (65%) |
83 (72%) |
|
Race |
|
|
|
0.51 |
American Indian/Alaska Native (n,%) |
0 (0%) |
0 (0%) |
3 (3%) |
|
Asian (n,%) |
28 (17%) |
5 (19%) |
13 (11%) |
|
Black or African American (n,%) |
30 (18%) |
5 (19%) |
19 (16%) |
|
Mixed race (n,%) |
5 (3%) |
1 (4%) |
5 (4%) |
|
Native Hawaiian or Other Pacific Islander (n,%) |
2 (1%) |
0 (0%) |
0
(0%) |
|
Unknown (n,%) |
6 (4%) |
1 (4%) |
9 (8%) |
|
White (n,%) |
93 (57%) |
14 (54%) |
67 (58%) |
|
Comorbidities |
|
|
|
|
Hypertension |
21 (13%) |
6 (23%) |
15 (13%) |
0.35 |
Diabetes |
9 (5%) |
1 (4%) |
5 (4%) |
0.91 |
Asthma |
61 (37%) |
11 (42%) |
44 (38%) |
0.89 |
Obesity (BMI>30) |
27 (19%) |
7 (30%) |
19 (18%) |
0.38 |
Other medications |
|
|
|
|
ACEi |
5 (3%) |
0 (0%) |
2 (2%) |
0.84 |
COVID exposure and testing |
|
|
|
|
Tested positive for COVID 19 (n,%) |
39 (24%) |
11 (42%) |
37 (32%) |
0.09 |
Exposure to positive COVID 19 (n,%) |
76 (46%) |
6 (23%) |
46 (40%) |
0.06 |
Exposure to COVID 19-like symptoms (n,%) |
49 (30%) |
9 (35%) |
33
(28%) |
0.84 |